Clinical trial NCT02283489: Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
Official title: Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Head and Neck Neoplasms
Keywords: Recombinant Human Endostatin Adenovirus
Head and Neck Malignant Tumor
clinical trial
randomized
Endostatin
gene therapy
Lead sponsor: Chengdu Shi Endor Biological Engineering Technology Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: West China Hospital
First posted: 2014-11-05
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.

Detailed description: Head and neck cancer is one of the most common malignant tumors in China, accounting for 19.9% to 30.2% of malignant tumors in this country. Approximately 60% to 70% of patients have stage III or IV disease at the time of diagnosis, and the 5-year overall survival is about 30%. The local recurrence rate ranges from 50% to 60%. The 5-year overall survival for patients treated with multidisciplinary treatment, which is a common treatment method that includes surgery, chemotherapy, radiotherapy, and biotherapy, has recently increased by 5%. Further improvements in the treatment effects of head and neck cancer are required.

Endostatin, an endogenous angiogenesis inhibitor and a C-terminal fragment of collagen XVIII, effectively inhibits tumor angiogenesis by specific inhibition of neovascular endothelial cells \[7, 8\]. Its characteristic antitumor effect is dose-dependent, requiring continuous high protein activity. Transportation of recombinant genes with adenovirus vectors into the body leads to continuous expression of high levels of endogenous secretory proteins, resolving the limitation of foreign protein infusion. Previous studies have shown that the antitumor activity of recombinant human endostatin adenovirus is higher than that of recombinant human endostatin protein.

EDS01, an antitumor gene therapy product that uses recombined adenovirus type 5 as the vector for the human endostatin gene, may be termed a recombinant adenovirus-recombined human endostatin gene. Intratumor injection of EDS01 reportedly results in transportation of the human endostatin gene into tumor cells by adenovirus infection, leading to the expression of endostatin protein. Expression of this protein inhibits neovascular endothelial cells, neovascularization, and tumor growth and metastasis. Both in vivo and in vitro experiments have shown that EDS01 significantly inhibits the growth of neovascular endothelial cells and tumor growth in nude mouse xenograft models of laryngocarcinoma and nasopharyngeal carcinoma.

A phase I clinical trial (No. treatment effect) conducted at West China Hospital of Sichuan University enrolled patients with superficial advanced head and neck cancer lesions. The patients underwent injection of different doses of EDS01, and the investigators performed a preliminary evaluation of the maximally tolerated dose and adverse events. The study showed that, whether administered by dose escalation or in multiple doses, EDS01 was well tolerated without dose-limiting toxicity and maximum tolerated dose. The main side effects were fever and injection site pain with flu-like symptoms. A small amount of EDS01 (1/10 000 000) was absorbed into the bloodstream. A thimbleful (1/100 000 000 to 1/10 000 000 000) was excreted in the urine and feces and was nontoxic to the environment. The target lesions exhibited a treatment response.

According to the results of this phase I trial, both 5.0 × 1011 and 1.0 × 1012 virus particles (VP) of EDS01 showed adequate safety and treatment responses. Therefore, in the subsequent phase II clinical trial, the optimal of these two doses will be determined. The treatment effects and safety of this protocol for head and neck cancer will also be further investigated.

In summary, this study will initially explore the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.

In the experimental group, the target lesion is defined as that injected by EDS01. In the control group, the target lesion is defined as that selected at the inception.

Eligibility criteria: Inclusion Criteria:

* Advanced head and neck cancer unsuitable for surgery or radiotherapy (including head and neck squamous carcinoma and nasopharyngeal carcinoma, which should not more than 30%)
* Cytological and/or histopathologic diagnosis
* Target lesions can be treated with intratumor injection
* Lesions can be measured by imaging with a diameter of ≥2 cm (RECIST1.1)
* No chemotherapy, radiotherapy, or biotherapy administered in the past 4 weeks
* Age of 18 to 70 years
* Life expectation of ≥12 weeks
* ECOG performance status of 0 to 2
* Laboratory examinations performed ≤7 days before enrollment with the following results: absolute neutrophil count of ≥1.5 × 109 L-1, platelet count of ≥80 × 109/L, total bilirubin level of ≤2 mg/dL, AST and ALT levels of ≤2 times the upper limit of the reference range, and coagulation parameters ≤1.5 times the upper limit of the reference range
* Voluntary participation and written informed consent

Exclusion Criteria:

* Allergy to EDS01
* Nerves and vessels passing through target lesions do not allow for injection of EDS01 into lesions
* Simultaneous radiation of target lesions
* Cancer recurrence within 6 months treated by paclitaxel
* Severe coagulation dysfunction and bleeding tendency
* Serious medical diseases, myocardial infraction in the past 3 months, or acute infection
* Currently pregnant or lactating
* Any conditions that the investigator regards as unsuitable for the study

Primary outcomes:
measure: Change in Objective response rate (ORR) of target lesion
timeFrame: During the 2nd and 4th cycle of treatment phase (day 35, day 76) and follow-up (every 3 months after treatment till 2 years).
Secondary outcomes:
measure: Change in Disease control rate of target lesion
timeFrame: During the 2nd and 4th cycle of treatment phase (day 35, day 76) and follow-up (every 3 months after treatment till 2 years).
measure: Change in ORR of all lesions
timeFrame: During the 2nd and 4th cycle of treatment phase (day 35, day 76) and follow-up (every 3 months after treatment till 2 years).
measure: Time to progression
timeFrame: Up to 24 weeks
measure: Change in Immune response
timeFrame: During the screening phase and on days 7, 21, 35, 48, 62, and 76 (day 1 is defined as the first day of chemotherapy with the TP regimen)
Other outcomes:
measure: Change in adenovirus in patients' secreta and excreta
timeFrame: Before the first administration and on days 1 and 3 after the first administration
measure: Change in vital signs and physique
timeFrame: Screening phase (before randomization) and treatment phase (until week 12 after treatment)
Locations:
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
city: Chengdu
country: China
facility: Sichuan Provincial People's Hospital
state: Sichuan
city: Chongqing
country: China
facility: Chongqing Cancer Hospital
city: Shanghai
country: China
facility: Shanghai Ninth People's Hospital Affiliated Shanghai JiaoTong University School of Medicine
Study officials:
affiliation: Chengdu Shi Endor Biological Engineering Technology Co., Ltd
name: Renmiao Zhang, MD, PhD
role: STUDY_DIRECTOR
References: